Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts

BenzingaDec 30 09:00 ET

Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target

BenzingaDec 30 08:23 ET · Ratings

Axsome Therapeutics Analyst Ratings

BenzingaDec 30 08:21 ET · Ratings

Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BenzingaDec 30 08:13 ET

Axsome Completes Phase 3 Trials for AXS-05 in Alzheimer's Agitation, Plans FDA Submission for Alzheimer's Agitation Drug in 2025

BenzingaDec 30 07:10 ET

Mizuho CEO Sees Global Boom in M&A After Trump Takes Office

BNN BloombergDec 24 03:00 ET